Perseus Proteomics, First Half Net Income Loss Narrows, Jul-Sep Net Income Loss Narrows

Fri Nov 14, 2025 3:30 pm JST Earnings

4882 Perseus Proteomics Inc. 【J-GAAP】

Perseus Proteomics Inc. <4882> [TSE Growth] announced its financial results after the market closed on November 14th (15:30). The net loss (non-consolidated) for the cumulative second quarter of the fiscal year ending March 2026 (April to September) was a reduced loss of 379 million yen (compared to a loss of 495 million yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the net loss improved to a deficit of 203 million yen (compared to a loss of 276 million yen in the same period last year). The operating profit/loss margin improved from -494.9% in the same period last year to -489.2%.

Kabutan News

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	50M	-444M	-429M	-633M	-53.9	ー	Nov 13, 2023	J-GAAP
Apr - Sep, 2024	59M	-414M	-427M	-495M	-35.9	ー	Nov 14, 2024	J-GAAP
Apr - Sep, 2025	60M	-399M	-345M	-379M	-25.7	ー	Nov 14, 2025	J-GAAP
YoY	+1.7%	+3.6%	+19.2%	+23.4%	+28.4%

First Half Results vs. Previous Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	ー	0	May 15, 2025	J-GAAP
Apr - Sep, 2025 Results	60M	-399M	-345M	-379M	-25.7	0	Nov 14, 2025	J-GAAP
Revision Rate	ー	ー	ー	ー	ー

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024	61M	-412M	-402M	-409M	-28.7	0	May 15, 2025	J-GAAP
Guidance Oct - Mar, 2025	ー	ー	ー	ー	ー	0	May 15, 2025	J-GAAP
YoY	ー	ー	ー	ー	ー

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	100M	-894M	-879M	-1,104M	-93.7	0	May 15, 2024	J-GAAP
Mar, 2025	120M	-826M	-829M	-904M	-63.4	0	May 15, 2025	J-GAAP
Guidance Mar, 2026	ー	ー	ー	ー	ー	0	May 15, 2025	J-GAAP
YoY	ー	ー	ー	ー	ー

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jul - Sep, 2024	39M	-193M	-213M	-276M	-20.0	-494.9%	Nov 14, 2024	J-GAAP
Oct - Dec, 2024	24M	-216M	-197M	-199M	-14.1	-900.0%	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	37M	-196M	-205M	-210M	-14.7	-529.7%	May 15, 2025	J-GAAP
Apr - Jun, 2025	23M	-218M	-171M	-176M	-11.9	-947.8%	Aug 14, 2025	J-GAAP
Jul - Sep, 2025	37M	-181M	-174M	-203M	-13.8	-489.2%	Nov 14, 2025	J-GAAP
YoY	-5.1%	+6.2%	+18.3%	+26.4%	+31.2%

Perseus Proteomics, First Half Net Income Loss Narrows, Jul-Sep Net Income Loss Narrows

Actual Performance and Financial Trends

Current Period Guidance

Quarterly Results

Related Articles